3-alkoxy-2-aminopropyamines, cardiovascular compositions and use
申请人:McNeilab, Inc.
公开号:US04758563A1
公开(公告)日:1988-07-19
Propylamines of the formula (I): ##STR1## and isomers thereof, particularly those enantiomers and racemates relative to the chiral carbon indicated by an asterisk (*). The propylamines can be used for the treatment of hypertension or angina in humans. A is pyrrolidine, piperidine or morpholine and B is an aromatic heterocycle, aromatic carbocycle or saturated carbocycle.
3-alkoxy-2-aminopropylamines useful as cardiovascular agents
申请人:McNeilab, Inc.
公开号:EP0237191A1
公开(公告)日:1987-09-16
Propylamines of the formula (I):
and isomers thereof, particularly those enantiomers and racemates relative to the chiral carbon indicated by an asterisk (*). The propylamines can be used for the treatment of hypertension or angina in humans. A is pyrrolidine, piperidine or morpholine and B is an aromatic heterocycle, aromatic carbocycle or saturated carbocycle, R1, R2 and R3 are lower alkyl groups a optionally joined to form a cycloalkyl or polycyclicalkyl group m is 0 or 1; Y is halo, alkyl, alkoxy, trifluoromethyl, hydroxy, or methylenedioxy; n is 0, 1, or 3.
SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS
申请人:Epizyme Inc
公开号:EP4105203A1
公开(公告)日:2022-12-21
The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds of formula (Va) to (Vf). The present disclosure also relates to pharmaceutical compositions containing these compounds. Said compounds are for use in methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2.
SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS
申请人:Epizyme Inc
公开号:EP3519393B1
公开(公告)日:2022-05-18
AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
申请人:Epizyme, Inc.
公开号:US20170355712A1
公开(公告)日:2017-12-14
The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.